PMID- 1655987
OWN - NLM
STAT- MEDLINE
DCOM- 19911118
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 9
IP  - 10
DP  - 1991 Oct
TI  - The treatment of Wilms' tumor patients with pulmonary metastases detected only 
      with computed tomography: a report from the National Wilms' Tumor Study.
PG  - 1776-81
AB  - To evaluate the prognosis of patients with Wilms' tumor who have pulmonary 
      densities identified on a computed tomographic (CT) scan of the chest, but have a 
      negative plain chest radiograph, we reviewed the treatments and outcome of 32 
      patients randomized or followed on National Wilms' Tumor Study (NWTS)-3. The 
      4-year event-free and overall survival percentages of 18 of these patients who 
      had a favorable histology tumor and were treated as stage IV tumors with three or 
      four drugs plus whole-lung irradiation were 88.1% and 94.0%, respectively. The 
      4-year event-free and overall survival percentages for nine favorable histology 
      patients treated less aggressively based on the extent of locoregional disease 
      with two or three drugs and without whole-lung irradiation were 88.9% and 88.0%, 
      respectively. There were no statistically significant differences in the 4-year 
      event-free or overall survival percentages between the two groups. The current 
      data do not demonstrate improved survival for favorable histology patients 
      treated with whole-lung irradiation for pulmonary metastases identified only on 
      chest CT scan. However, due to the small number of patients included, no 
      statistically valid conclusions regarding the roles of Adriamycin (doxorubicin; 
      Adria Laboratories, Columbus, OH) and/or whole-lung irradiation in the treatment 
      of these patients can be drawn from the present analysis. Additional patients 
      need to be systematically studied to determine if these preliminary observations 
      can be confirmed.
FAU - Green, D M
AU  - Green DM
AD  - Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, NY 14263.
FAU - Fernbach, D J
AU  - Fernbach DJ
FAU - Norkool, P
AU  - Norkool P
FAU - Kollia, G
AU  - Kollia G
FAU - D'Angio, G J
AU  - D'Angio GJ
LA  - eng
GR  - CA-09168/CA/NCI NIH HHS/United States
GR  - CA-42326/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 1CC1JFE158 (Dactinomycin)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Child
MH  - Combined Modality Therapy
MH  - Cyclophosphamide/administration & dosage
MH  - Dactinomycin/administration & dosage
MH  - Doxorubicin/administration & dosage
MH  - Humans
MH  - Kidney Neoplasms/*pathology
MH  - Lung Neoplasms/diagnostic imaging/secondary/*therapy
MH  - Proportional Hazards Models
MH  - Survival Analysis
MH  - Tomography, X-Ray Computed
MH  - Vincristine/administration & dosage
MH  - Wilms Tumor/diagnostic imaging/secondary/*therapy
EDAT- 1991/10/01 00:00
MHDA- 1991/10/01 00:01
CRDT- 1991/10/01 00:00
PHST- 1991/10/01 00:00 [pubmed]
PHST- 1991/10/01 00:01 [medline]
PHST- 1991/10/01 00:00 [entrez]
AID - 10.1200/JCO.1991.9.10.1776 [doi]
PST - ppublish
SO  - J Clin Oncol. 1991 Oct;9(10):1776-81. doi: 10.1200/JCO.1991.9.10.1776.